AIRNA's Reversible Gene Fix for AATD Enters Human Trials

CAMBRIDGE, MA – April 07, 2026 – Biotech firm AIRNA has initiated a new chapter in the fight against a debilitating genetic disorder, announcing that the first patient has been dosed in a global Phase 1 clinical trial for AIR-001. The experimental therapy is a novel RNA-editing candidate designed to treat alpha-1 antitrypsin deficiency (AATD), a condition that ravages both the lungs and the liver.

The milestone, which moves a promising new class of medicine from the lab into human testing, was accompanied by the news that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to AIR-001. This designation underscores the significant unmet need for AATD patients and provides regulatory and financial incentives to accelerate the drug's development.

A Novel Approach to Editing a Genetic Mistake

At the heart of AIRNA’s strategy is a cutting-edge technology known as RNA editing. Unlike gene-editing techniques such as CRISPR that make permanent, irreversible changes to a person’s DNA, RNA editing works one step downstream. It makes precise corrections to messenger RNA (mRNA)—the temporary genetic blueprints that cells use to build proteins.

AIR-001 is an oligonucleotide designed to harness the body's own cellular machinery. Delivered via a subcutaneous injection, it recruits naturally occurring enzymes called ADAR (Adenosine Deaminase Acting on RNA) to a specific spot on the mRNA produced from the mutated SERPINA1 gene, the culprit behind most AATD cases. The ADAR enzyme then chemically converts a single incorrect genetic "letter" into the correct one, effectively repairing the instructions before a faulty protein can be made.

Because RNA molecules are transient and constantly being replaced by the cell, the effect of the therapy is reversible and requires repeat dosing. This is seen by many in the field as a significant safety advantage over permanent DNA alterations, as it allows for treatment to be adjusted or stopped if necessary.

“RNA editing has the potential to deliver functional cures to people living with inherited diseases like AATD,” said Jacob S. Elkins, M.D., Chief Medical Officer of AIRNA, in a statement. “Promising preclinical data indicate AIR-001 has the potential to increase functional AAT levels to address both the lung and liver manifestations of AATD, with a reversible and repeatable dosing approach.”

Tackling a Two-Front Disease

AATD presents a cruel duality for patients. The genetic defect leads to a "loss-of-function" problem in the lungs and a "toxic gain-of-function" problem in the liver. In healthy individuals, the liver produces alpha-1 antitrypsin (AAT) protein, which travels to the lungs to protect them from damage caused by inflammation. In AATD, the most common PiZ mutation causes the AAT protein to misfold.

This misfolding prevents the protein from leaving the liver, leading to a dangerous buildup that can cause inflammation, scarring (fibrosis), cirrhosis, and an increased risk of liver cancer. Simultaneously, the lack of protective AAT protein in the lungs leaves them vulnerable to attack from an enzyme called neutrophil elastase, resulting in progressive, emphysema-like lung destruction.

Current treatments are limited and only address part of the problem. The standard of care for lung disease is augmentation therapy, which involves lifelong weekly intravenous infusions of AAT protein derived from donated plasma. While it can slow lung deterioration, it does not help the liver, cannot reverse damage, and is a significant treatment burden for patients. For the liver disease, no approved therapies exist, with liver transplantation being the only definitive option for end-stage disease.

AIRNA’s approach with AIR-001 aims to be a comprehensive solution. By correcting the mRNA, it is designed to enable the production of normal, functional AAT protein. This could simultaneously relieve the toxic protein burden on the liver and restore protective levels of AAT in the bloodstream to shield the lungs. Preclinical data presented by the company has shown the therapy led to a greater than 17-fold increase in the protein's lung-protective capacity and an approximately 9-fold reduction in the toxic protein aggregates in the liver, bolstering hopes that it can effectively fight the disease on both fronts.

Navigating a Competitive and High-Stakes Market

AIRNA enters a dynamic and competitive field, with several companies pursuing novel therapies for AATD. Arrowhead Pharmaceuticals, in partnership with Takeda, is developing Fazirsiran, an RNA interference (RNAi) drug that is further along in clinical trials. Fazirsiran works by "silencing" the mutated gene to reduce the toxic protein in the liver, but it does not restore the protective protein for the lungs.

Other competitors are exploring permanent genetic fixes. Beam Therapeutics is testing a base editor in clinical trials that directly corrects the DNA mutation, while Wave Life Sciences is also developing an ADAR-mediated RNA editor. AIRNA executives believe their platform's potency in producing functional AAT protein, combined with a strong safety profile and convenient subcutaneous dosing, could position AIR-001 as a best-in-class option.

The recently granted Orphan Drug Designation provides a significant strategic advantage. It secures seven years of market exclusivity in the U.S. should AIR-001 gain approval, protecting it from competition. The designation also provides tax credits for clinical trials and waivers for expensive FDA application fees, reducing the financial risk of developing a drug for a rare disease. The AATD market, valued at over $2.6 billion in 2023, is projected to grow substantially, making it an attractive target for innovative therapies.

The Road Ahead for RepAIR1

The Phase 1 clinical trial, named RepAIR1, is an open-label study designed to evaluate the safety, tolerability, and activity of AIR-001 in approximately 54 adults with the severe PiZZ genotype of AATD. The study will assess both single ascending doses and multiple doses to find an optimal regimen. Researchers will closely monitor changes in various forms of the AAT protein in the blood to see if the drug is working as intended.

The trial has received regulatory authorization in multiple countries and is currently enrolling patients in Australia and the United Kingdom. AIRNA expects to expand the study to an estimated 20 sites across 11 countries.

For the thousands of individuals living with AATD, the start of the RepAIR1 trial represents a tangible step toward a potential future where a single therapy could address the root cause of their complex disease. The journey through clinical trials is long, but the prospect of a reversible, dual-action treatment offers a powerful new form of hope.